ReviewInternational journal of molecular sciences2021
Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Immune cells in keloids: mechanisms and potential treatments.Annals of medicine · 2026Review
- From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis AgainstPharmaceutics · 2026Review
- The Role of Vitamin D in Autoimmune Diseases.International journal of molecular sciences · 2026Review
- Innovative approaches targeting innate immune cells to promote organ transplant tolerance.Frontiers in transplantation · 2026Review
- Restoring Immunological Tolerance via Dendritic Cells in Rheumatoid Arthritis.European journal of immunology · 2026Review
- M2 macrophage polarization in allogeneic skin transplantation: from intrinsic mechanisms to clinical prospects for immune tolerance.Molecular biology reports · 2025Review
- Induction of Tolerogenic Dendritic Cells by a Noncoding Oligonucleotide.European journal of immunology · 2025Article
- Immune Responses of Dendritic Cells to Zoonotic DNA and RNA Viruses.Veterinary sciences · 2025Review
- Targeting Recipient Dendritic Cells with Sialic Acid-Modified Donor Alloantigen Prolongs Skin Transplant Survival.International journal of molecular sciences · 2025Article
- Harnessing bioengineered myeloid progenitors for precision immunotherapies.NPJ Regenerative medicine · 2023Review
- Decreased DIO3OS Expression Predicts Poor Prognosis in Hepatocellular Carcinoma and is Associated with Immune Infiltration.Biochemical genetics · 2023Article
- Metformin induces tolerogenicity of dendritic cells by promoting metabolic reprogramming.Cellular and molecular life sciences : CMLS · 2023Article
- Macrophages in immunoregulation and therapeutics.Signal transduction and targeted therapy · 2023Review
- 1,25(OH)International journal of molecular sciences · 2023Article
- New approaches to immunotherapy in house dust mite allergy.Clinical and experimental pediatrics · 2023Article
- A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome.iScience · 2023Article
- Novel potential therapeutic targets of alopecia areata.Frontiers in immunology · 2023Review
- Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.Frontiers in immunology · 2023Review
- Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance.Frontiers in bioengineering and biotechnology · 2023Review
- Sinomenine promotes differentiation of induced pluripotent stem cells into immature dendritic cells with high induction of immune tolerance.World journal of stem cells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Myeloid regulatory cell-based therapy has been shown to be a promising cell-based medicinal approach in organ transplantation and for the treatment of autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis, Crohn's disease and multiple sclerosis. Dendritic cells (DCs) are the most efficient antigen-presenting cells and can naturally acquire tolerogenic properties through a variety of differentiation signals and stimuli. Several subtypes of DCs have been generated using additional agents, including vitamin D3, rapamycin and dexamethasone, or immunosuppressive cytokines, such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). These cells have been extensively studied in animals and humans to develop clinical-grade tolerogenic (tol)DCs. Regulatory macrophages (Mregs) are another type of protective myeloid cell that provide a tolerogenic environment, and have mainly been studied within the context of research on organ transplantation. This review aims to thoroughly describe the ex vivo generation of tolDCs and Mregs, their mechanism of action, as well as their therapeutic application and assessment in human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.